Our long term goal is to understand the molecular mechanisms by which viruses occasionally jump from their
normal host species to a new species, a process that may lead to emerging viral diseases in the new host
species. We will focus on the interactions of the spike glycoprotein of murine coronavirus MHV with host cell
receptors in the CEA family of glycoproteins. Several labs have shown that persistent infection of murine cell
lines with MHV leads to markedly reduced expression of the CEACAMla receptor glycoprotein. In the
persistently infected cultures, viruses with mutations in their spike glycoproteins and some other genes
rapidly replace the wild type virus. The mutations in the spike genes are associated with acquisition of the
ability of the virus to replicate in cell lines from cats, pigs, rats, monkeys and humans. We will identify amino
acid residues in both the viral spike glycoprotein and the CEACAMla receptor that determine the specificity
of binding virus. We will study the effects of mutations in S and in the receptor upon the specificity of
virus-receptor interactions. We will continue our work on determining the crystal structures of CEACAM1
proteins to learn how the functional CEACAMla receptor differs from CEACAM1 b proteins from
MHV-resistant mice and human CEACAMI. We will engineer spike and receptor proteins that will form
co-crystals in order to determine the crystal structure of the complex. We will analyze the conformational
changes in the viral spike protein induced by soluble receptor or by pH 8 at 37oC that are associated with
membrane fusion and virus entry. To develop strains of inbred mice that are resistant to MHV infection, we
will manipulate the Ceacaml gene in mice to reduce or eliminate expression of CEACAM1 proteins. We will
also substitute chimeric CeacamlaJl b genes for the normal Ceacaml gene in mice. The animals will be
tested for MHV-susceptibility and immune responses. These studies will provide important information about
the mechanism of changing receptor specificity in a model virus that causes disease in its natural host.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
041096314
UEI
MW8JHK6ZYEX8
Project Start Date
01-February-1988
Project End Date
31-December-2008
Budget Start Date
01-January-2007
Budget End Date
31-December-2008
Project Funding Information for 2007
Total Funding
$525,523
Direct Costs
$371,562
Indirect Costs
$153,961
Year
Funding IC
FY Total Cost by IC
2007
National Institute of Allergy and Infectious Diseases
$525,523
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI025231-20
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI025231-20
Patents
No Patents information available for 5R01AI025231-20
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI025231-20
Clinical Studies
No Clinical Studies information available for 5R01AI025231-20
News and More
Related News Releases
No news release information available for 5R01AI025231-20
History
No Historical information available for 5R01AI025231-20
Similar Projects
No Similar Projects information available for 5R01AI025231-20